<?xml version="1.0" encoding="UTF-8"?>
<p>In vivo data from the AMAZES study, the largest clinical trial of a long‐term macrolide in airways disease, showed a striking 40% reduction in asthma exacerbations with AZM.
 <xref rid="rmv2163-bib-0029" ref-type="ref">
  <sup>29</sup>
 </xref> The mechanism is unknown, and would be consistent with an anti‐viral effect, although metagenomic analyses suggest an antibacterial effect reducing 
 <italic>Haemophilus influenzae</italic>
 <xref rid="rmv2163-bib-0033" ref-type="ref">
  <sup>33</sup>
 </xref>, 
 <xref rid="rmv2163-bib-0034" ref-type="ref">
  <sup>34</sup>
 </xref> may be the predominant mechanism. The effect on viruses may relate to 
 <italic>H. influenzae</italic> upregulation of ICAM‐1, a major receptor for both 
 <italic>Haemophilus</italic> and rhinovirus (RV).
 <xref rid="rmv2163-bib-0035" ref-type="ref">
  <sup>35</sup>
 </xref>
</p>
